Stereotaxis Reports 2023 Second Quarter Financial Results
- Stereotaxis delivered 28% revenue growth in Q2 2023
- Received orders for two Genesis systems
- System backlog of $16 million
- Strategic collaboration with Abbott for integration of EnSite X mapping system
- Advancement of next-generation highly-accessible robot on track
- Confident in balance sheet and anticipate reduced cash utilization
- None.
ST. LOUIS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2023.
“Stereotaxis delivered
“Stereotaxis continues to advance a robust innovation strategy. During the quarter we announced a significant strategic collaboration with Abbott to integrate the EnSite X mapping system with our robotic technology. Successful joint integrated procedures have begun in Europe and we expect growing adoption in the coming months. We rapidly responded to the request for first-in-human data to support CE Mark of the MAGiC catheter and have submitted documentation to initiate a study. Development of our next-generation highly-accessible robot remains on track. We are excited by the strategic transformation underway as we advance a new foundational product ecosystem that makes robotics broadly accessible and impactful across endovascular surgery.”
“We remain cognizant of the importance of maintaining financial strength and discipline. We are confident in our balance sheet and anticipate reduced cash utilization in upcoming quarters. Our clean balance sheet allows us to advance our transformative product ecosystem to market, fund its commercialization, and reach profitability without the need for additional financing.”
2023 Second Quarter Financial Results
Revenue for the second quarter of 2023 totaled
Gross margin for the second quarter of 2023 was
Operating loss and net loss for the second quarter of 2023 were (
Cash Balance and Liquidity
At June 30, 2023, Stereotaxis had cash and cash equivalents, including restricted cash, of
Forward Looking Expectations
Stereotaxis reiterates its expectation of double-digit revenue growth in 2023 driven by revenue recognition of system backlog and new system orders. Accelerating revenue growth in subsequent years is expected to be supported by new technology launches.
Stereotaxis expects to end the year with
Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, August 10, 2023, at 10:00 a.m. Eastern Time. To access the conference call, dial 1-800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 5648825. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at https://ir.stereotaxis.com/.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
STEREOTAXIS, INC. | |||||||||||||||
STATEMENTS OF OPERATIONS | |||||||||||||||
(Unaudited) | |||||||||||||||
(in thousands, except share and per share amounts) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Revenue: | |||||||||||||||
Systems | $ | 3,313 | $ | 602 | $ | 5,134 | $ | 2,236 | |||||||
Disposables, service and accessories | 4,546 | 5,550 | 9,273 | 10,953 | |||||||||||
Total revenue | 7,859 | 6,152 | 14,407 | 13,189 | |||||||||||
Cost of revenue: | |||||||||||||||
Systems | 2,703 | 509 | 4,400 | 1,801 | |||||||||||
Disposables, service and accessories | 969 | 973 | 1,944 | 1,794 | |||||||||||
Total cost of revenue | 3,672 | 1,482 | 6,344 | 3,595 | |||||||||||
Gross margin | 4,187 | 4,670 | 8,063 | 9,594 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 2,647 | 2,893 | 5,393 | 5,340 | |||||||||||
Sales and marketing | 3,340 | 3,279 | 6,488 | 6,225 | |||||||||||
General and administrative | 3,477 | 3,677 | 7,078 | 7,297 | |||||||||||
Total operating expenses | 9,464 | 9,849 | 18,959 | 18,862 | |||||||||||
Operating loss | (5,277 | ) | (5,179 | ) | (10,896 | ) | (9,268 | ) | |||||||
Other income | 27 | - | 27 | - | |||||||||||
Interest income, net | 293 | 45 | 565 | 48 | |||||||||||
Net loss | $ | (4,957 | ) | $ | (5,134 | ) | $ | (10,304 | ) | $ | (9,220 | ) | |||
Cumulative dividend on convertible preferred stock | (335 | ) | (335 | ) | (666 | ) | (666 | ) | |||||||
Net loss attributable to common stockholders | $ | (5,292 | ) | $ | (5,469 | ) | $ | (10,970 | ) | $ | (9,886 | ) | |||
Net loss per share attributed to common stockholders: | |||||||||||||||
Basic | $ | (0.07 | ) | $ | (0.07 | ) | $ | (0.14 | ) | $ | (0.13 | ) | |||
- | |||||||||||||||
Diluted | $ | (0.07 | ) | $ | (0.07 | ) | $ | (0.14 | ) | $ | (0.13 | ) | |||
Weighted average number of common shares and equivalents: | |||||||||||||||
Basic | 81,049,211 | 75,953,916 | 78,787,652 | 75,915,864 | |||||||||||
Diluted | 81,049,211 | 75,953,916 | 78,787,652 | 75,915,864 | |||||||||||
STEREOTAXIS, INC. | |||||||
BALANCE SHEETS | |||||||
(in thousands, except share amounts) | June 30, 2023 | December 31, 2022 | |||||
(Unaudited) | |||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 22,877 | $ | 8,586 | |||
Restricted cash - current | 569 | 525 | |||||
Short-term investments | - | 19,844 | |||||
Accounts receivable, net of allowance of | 6,645 | 5,090 | |||||
Inventories, net | 7,703 | 7,876 | |||||
Prepaid expenses and other current assets | 1,108 | 1,325 | |||||
Total current assets | 38,902 | 43,246 | |||||
Property and equipment, net | 3,590 | 3,831 | |||||
Restricted cash | 481 | 744 | |||||
Operating lease right-of-use assets | 5,188 | 5,384 | |||||
Prepaid and other non-current assets | 154 | 208 | |||||
Total assets | $ | 48,315 | $ | 53,413 | |||
Liabilities and stockholders’ equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 2,840 | $ | 3,270 | |||
Accrued liabilities | 2,920 | 3,306 | |||||
Deferred revenue | 8,223 | 7,342 | |||||
Current portion of operating lease liabilities | 399 | 373 | |||||
Total current liabilities | 14,382 | 14,291 | |||||
Long-term deferred revenue | 1,639 | 1,654 | |||||
Operating lease liabilities | 5,282 | 5,488 | |||||
Other liabilities | 43 | 51 | |||||
Total liabilities | 21,346 | 21,484 | |||||
Series A - Convertible preferred stock: | |||||||
Convertible preferred stock, Series A, par value | 5,583 | 5,583 | |||||
Stockholders’ equity: | |||||||
Convertible preferred stock, Series B, par value | - | 6 | |||||
Common stock, par value | 81 | 75 | |||||
Additional paid-in capital | 548,782 | 543,438 | |||||
Treasury stock, 4,015 shares at 2023 and 2022 | (206 | ) | (206 | ) | |||
Accumulated deficit | (527,271 | ) | (516,967 | ) | |||
Total stockholders’ equity | 21,386 | 26,346 | |||||
Total liabilities and stockholders’ equity | $ | 48,315 | $ | 53,413 |
FAQ
What was Stereotaxis' revenue growth in Q2 2023?
How many Genesis systems did Stereotaxis receive orders for in Q2 2023?
What is the system backlog for Stereotaxis?
What is the strategic collaboration announced by Stereotaxis?
What advancements are being made in Stereotaxis' robotic technology?